 2. For the patients, diagnoses of schizophrenia will be confirmed using the Chinese version of the Mini International Neuropsychiatric Interview MINI. At the baseline and Week 12, patient blood samples will be obtained to measure the levels of neuroendocrine substrates didehydroepiandrosterone, dehydroepiandrosterone sulfate, pregnenolone, and cortisol and metabolite markers lipid profiles, glycerate, eicosenoic acid, pyruvate, b-hydroxybutyrate, Cysteine. Cognitive function will be evaluated using the Brief Assessment of Cognition in Schizophrenia. The participants clinical symptoms and daily activities will be assessed using the Positive and Negative Syndrome Scale, 17-item Hamilton Depression Rating Scale, and Personal and Social Performance Scale. 